



**Jubilant Life Sciences Ltd.**  
1A, Sector 16A, Noida – 201301, India  
Tel.: +91 120 4361000  
[www.jubl.com](http://www.jubl.com)

## **Results of Tender Offer for acquisition of minority shares of Cadista Holdings Inc.**

***Noida (UP), India, Tuesday, December 23, 2014***

Jubilant Life Sciences Limited (“Jubilant Life Sciences”) announced today that its indirect wholly-owned subsidiary, Jubilant Generics Inc. (“Jubilant Generics”), has successfully completed its previously announced Tender Offer for all of the outstanding shares of Cadista Holdings Inc. (“Cadista Holdings”) common stock not owned by Jubilant Generics or its affiliates. The Tender Offer expired at 5:00 PM., New York City time, on Friday, December 19, 2014.

Based upon information provided by the depository for the Tender Offer, as of the expiration of the Tender Offer, a total of 17,018,378 shares were validly tendered and not withdrawn in the Tender Offer, representing approximately 82% of Cadista Holdings’ currently outstanding shares not already owned by Jubilant Generics and its affiliates. Jubilant Generics has accepted for payment all validly tendered shares.

Jubilant Life Sciences has caused Jubilant Generics to complete a short-form merger with and into Cadista Holdings. No vote of Cadista Holdings’ stockholders was required in connection with the merger. As a result of the merger, all shares of Cadista Holdings held by the remaining minority stockholders of Cadista Holdings have been cancelled and, subject to appraisal rights under Delaware Law, converted into the right to receive a \$1.60 per share in cash, without interest and less any required withholding taxes, the same consideration paid in the Tender Offer.

Accordingly, Cadista Holdings has now become a wholly-owned subsidiary of Jubilant Life Sciences Limited.

### **About Jubilant Life Sciences**

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery and Development. The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of about 6,200 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: [www.jubl.com](http://www.jubl.com).



**For more information please contact:**

**For Investors**

Ravi Agrawal  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1002  
E-mail: [ravi\\_agrawal@jubl.com](mailto:ravi_agrawal@jubl.com)

Siddharth Rangnekar  
Citigate Dewe Rogerson  
Tel: +91 22 6645 1209  
E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)

Anupam Jain  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1021  
E-mail: [anupam\\_jain@jubl.com](mailto:anupam_jain@jubl.com)

Karl Kolah  
Citigate Dewe Rogerson  
Tel: +91 22 6645 1220  
E-mail: [karl@cdr-india.com](mailto:karl@cdr-india.com)

**For Media**

Neha Garg  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1067  
E-mail: [neha\\_garg@jubl.com](mailto:neha_garg@jubl.com)

Saurabh Gupta  
Perfect Relations  
Ph: +91 9818075578  
E-mail: [sgupta@perfectrelations.com](mailto:sgupta@perfectrelations.com)

*Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*